MX2014014937A - Difluoro-hexahidro-ciclopentaoxazinilos y difluoro-hexahidro-benzo oxazinilos como inhibidores de beta-secretasa 1 (bace1). - Google Patents

Difluoro-hexahidro-ciclopentaoxazinilos y difluoro-hexahidro-benzo oxazinilos como inhibidores de beta-secretasa 1 (bace1).

Info

Publication number
MX2014014937A
MX2014014937A MX2014014937A MX2014014937A MX2014014937A MX 2014014937 A MX2014014937 A MX 2014014937A MX 2014014937 A MX2014014937 A MX 2014014937A MX 2014014937 A MX2014014937 A MX 2014014937A MX 2014014937 A MX2014014937 A MX 2014014937A
Authority
MX
Mexico
Prior art keywords
difluoro
hexahydro
cyclopentaoxazinyls
zooxazinyls
ben
Prior art date
Application number
MX2014014937A
Other languages
English (en)
Inventor
Hans Hilpert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014014937A publication Critical patent/MX2014014937A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a difluorociclopentaoxazinilos y difluoroenzooxazinilos de la fórmula I que tienen actividad inhibidora BACE1, su manufactura, composiciones farmacéuticas que los contienen y su uso como sustancias terapéuticamente activas. Los compuestos activos de la presente invención son útiles en el tratamiento terapéutico y/o profiláctico de, por ejemplo, la enfermedad de Alzheimer.
MX2014014937A 2012-06-26 2013-06-24 Difluoro-hexahidro-ciclopentaoxazinilos y difluoro-hexahidro-benzo oxazinilos como inhibidores de beta-secretasa 1 (bace1). MX2014014937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12173690 2012-06-26
PCT/EP2013/063086 WO2014001228A1 (en) 2012-06-26 2013-06-24 Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors

Publications (1)

Publication Number Publication Date
MX2014014937A true MX2014014937A (es) 2015-03-09

Family

ID=48672630

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014937A MX2014014937A (es) 2012-06-26 2013-06-24 Difluoro-hexahidro-ciclopentaoxazinilos y difluoro-hexahidro-benzo oxazinilos como inhibidores de beta-secretasa 1 (bace1).

Country Status (22)

Country Link
US (1) US9181232B2 (es)
EP (1) EP2864324B1 (es)
JP (1) JP6251257B2 (es)
KR (1) KR20150023450A (es)
CN (1) CN104470915B (es)
AU (1) AU2013283524B2 (es)
BR (1) BR112014029742A2 (es)
CA (1) CA2872181A1 (es)
CL (1) CL2014003325A1 (es)
CO (1) CO7151509A2 (es)
CR (1) CR20140528A (es)
EA (1) EA025273B1 (es)
HK (1) HK1206344A1 (es)
IL (1) IL236138A (es)
MA (1) MA37763B1 (es)
MX (1) MX2014014937A (es)
NZ (1) NZ702253A (es)
PE (1) PE20142450A1 (es)
PH (1) PH12014502623B1 (es)
SG (1) SG11201407576YA (es)
UA (1) UA113309C2 (es)
WO (1) WO2014001228A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
SG11201507196WA (en) 2013-03-08 2015-10-29 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
MX2017001794A (es) 2014-08-08 2017-06-29 Amgen Inc Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
WO2016150785A1 (en) 2015-03-20 2016-09-29 F. Hoffmann-La Roche Ag Bace1 inhibitors
BR112020021728A2 (pt) 2018-04-27 2021-01-26 Shionogi & Co., Ltd. derivados de tetra-hidropiranooxazina tendo atividade inibitória de bace1 seletiva

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
BR112012013854A2 (pt) * 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.

Also Published As

Publication number Publication date
MA37763B1 (fr) 2017-05-31
EA201590066A1 (ru) 2015-04-30
IL236138A0 (en) 2015-02-01
PE20142450A1 (es) 2015-01-28
EP2864324B1 (en) 2018-03-28
JP2015521640A (ja) 2015-07-30
CN104470915A (zh) 2015-03-25
US20150133440A1 (en) 2015-05-14
CO7151509A2 (es) 2014-12-29
BR112014029742A2 (pt) 2017-06-27
EP2864324A1 (en) 2015-04-29
AU2013283524A1 (en) 2014-11-13
JP6251257B2 (ja) 2017-12-20
WO2014001228A1 (en) 2014-01-03
HK1206344A1 (en) 2016-01-08
PH12014502623A1 (en) 2015-01-21
NZ702253A (en) 2016-06-24
CR20140528A (es) 2015-01-12
CA2872181A1 (en) 2014-01-03
AU2013283524B2 (en) 2017-03-30
IL236138A (en) 2016-10-31
MA37763A1 (fr) 2016-08-31
CL2014003325A1 (es) 2015-04-24
US9181232B2 (en) 2015-11-10
KR20150023450A (ko) 2015-03-05
SG11201407576YA (en) 2015-03-30
CN104470915B (zh) 2019-07-26
PH12014502623B1 (en) 2015-01-21
UA113309C2 (xx) 2017-01-10
EA025273B1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX2013013692A (es) Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2).
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
PH12015502365A1 (en) Bace1 inhibitors
MX2013010795A (es) 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2).
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
EA201391752A1 (ru) Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2013014007A (es) [1,3] oxazinas.
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
PH12015500730A1 (en) Inhibitors of histone demethylases
EA201391670A1 (ru) 1,3-оксазины в качестве ингибиторов bace1 и/или bace2
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
MX2013008213A (es) N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
PH12017501668A1 (en) Bace1 inhibitors
MX2016006906A (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
MX2013002398A (es) Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators